▸ 29 Sep 2026, 10:34 Trofinetide US patent protections extended to March 2041 Company Update
▸ 29 Sep 2026, 09:59 Pause in Trading Trading Halt / Suspension
▸ 18 Sep 2026, 16:12 Update - Dividend/Distribution - NEU Dividends & Distributions
▸ 2 Sep 2026, 08:50 Corporate Presentation, 2 September 2026 Presentations
▸ 26 Aug 2026, 16:56 Dividend/Distribution - NEU Dividends & Distributions
▸ 26 Aug 2026, 10:40 Investor presentation, 26 August 2026 Financial Results
▸ 26 Aug 2026, 09:47 Growing royalty anchors Neuren first ever dividend program Financial Results
▸ 26 Aug 2026, 09:25 Half Yearly Report and Accounts Financial Results
▸ 25 Aug 2026, 08:31 European Commission grants marketing authorisation for DAYBU Company Update
▸ 21 Aug 2026, 15:19 Neuren H1 2026 Financial Results Webinar on 26 August 2026 Presentations
▸ 5 Aug 2026, 09:52 Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded Company Update
▸ 24 Jul 2026, 09:57 Neuren highlights participation in PMSF Family Conference Company Administration
▸ 29 Jun 2026, 07:43 DAYBU recommended for approval in the European Union Company Update
▸ 18 Jun 2026, 16:49 Application for quotation of securities - NEU Securities Administration
▸ 1 Jun 2026, 17:47 Notification of cessation of securities - NEU Securities Administration
▸ 1 Jun 2026, 17:40 Notification regarding unquoted securities - NEU Securities Administration
▸ 27 May 2026, 16:00 Results of Meeting Meetings & Governance
▸ 27 May 2026, 13:22 AGM Chair Address & CEO Presentation Presentations
▸ 14 May 2026, 07:30 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 12 May 2026, 15:56 Launch of Investor Hub to enhance shareholder engagement Company Administration
▸ 12 May 2026, 08:34 Notification of cessation of securities - NEU Securities Administration
▸ 12 May 2026, 08:32 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 11 May 2026, 08:45 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 7 May 2026, 09:53 Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025 Company Update
▸ 6 May 2026, 10:31 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 29 Apr 2026, 08:45 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 24 Apr 2026, 13:27 Virtual AGM online guide Meetings & Governance
▸ 24 Apr 2026, 13:22 Notice of Annual General Meeting/Proxy Form Meetings & Governance
▸ 24 Apr 2026, 13:05 Appendix 4G Company Administration
▸ 24 Apr 2026, 12:58 2025 Annual Report to shareholders Financial Results
▸ 21 Apr 2026, 08:56 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 20 Apr 2026, 08:32 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 17 Apr 2026, 08:48 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 10 Apr 2026, 16:55 Notification of cessation of securities - NEU Securities Administration
▸ 8 Apr 2026, 09:47 DAYBUE STIX now broadly available in US for Rett syndrome Company Update
▸ 26 Mar 2026, 17:49 Notification of cessation of securities - NEU Securities Administration
▸ 24 Mar 2026, 08:40 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 13 Mar 2026, 08:26 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 10 Mar 2026, 08:40 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 6 Mar 2026, 10:25 Change of Director's Interest Notice - J Basile Director Interests
▸ 4 Mar 2026, 08:42 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 3 Mar 2026, 09:50 Acadia confirms plan to request CHMP re-examination Company Update
▸ 27 Feb 2026, 11:54 Investor presentation, 27 February 2026 Presentations
▸ 27 Feb 2026, 09:59 2025 royalty income A$65m, profit after tax A$30m Financial Results
▸ 27 Feb 2026, 09:53 Appendix 4E and 2025 full year accounts Financial Results
▸ 26 Feb 2026, 11:15 Acadia reports DAYBUE net sales for 2025 and 2026 guidance Company Update
▸ 26 Feb 2026, 09:53 Pause in Trading Trading Halt / Suspension
▸ 13 Feb 2026, 09:32 Update - Notification of buy-back - NEU Buybacks & Capital Management
▸ 11 Feb 2026, 18:24 Notification of buy-back - NEU Buybacks & Capital Management
▸ 11 Feb 2026, 17:05 Notification of Neuren investor webinar on 12 February 2026 Presentations
▸ 11 Feb 2026, 17:00 Neuren to commence new on-market share buy-back program Buybacks & Capital Management
▸ 6 Feb 2026, 09:26 First patient dosed in Neuren PMS Phase 3 trial Company Update
▸ 5 Feb 2026, 08:11 Priority Review Voucher program reauthorized by US Congress Company Administration
▸ 4 Feb 2026, 17:07 Neuren receives US FDA meeting feeback for HIE and PTHS Company Update
▸ 4 Feb 2026, 10:14 Trading Halt Trading Halt / Suspension
▸ 4 Feb 2026, 09:57 Pause in Trading Trading Halt / Suspension
▸ 3 Feb 2026, 09:40 Acadia provides update on EU regulatory submission Company Update
▸ 19 Jan 2026, 09:10 Response to ASX Aware Letter ASX Query
▸ 14 Jan 2026, 10:26 DAYBUE net sales projected to reach approx US$700m in 2028 Company Update
▸ 7 Jan 2026, 10:20 NNZ-2591 PMS Phase 2 trial published in Neurology Genetics Company Update
▸ 22 Dec 2025, 09:48 Health Canada approves Clinical Trial Application for Koala Company Update
▸ 15 Dec 2025, 09:05 FDA approves DAYBUE STIX (trofinetide), powder formulation Company Update
▸ 9 Dec 2025, 10:38 One-month administrative delay to FDA meeting for HIE Company Update
▸ 24 Nov 2025, 17:43 Application for quotation of securities - NEU Securities Administration
▸ 10 Nov 2025, 08:46 Investor Presentation, 10 November 2025 Presentations
▸ 6 Nov 2025, 09:59 Record DAYBUE net sales of US$101.1 million in Q3 2025 Company Update
▸ 20 Oct 2025, 09:28 Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid Company Update
▸ 17 Oct 2025, 16:44 Change of registered office in Australia Securities Administration
▸ 3 Oct 2025, 16:58 Application for quotation of securities - NEU Securities Administration
▸ 22 Sep 2025, 07:30 Notification regarding unquoted securities - NEU Securities Administration
▸ 9 Sep 2025, 07:30 Neuren partners with Hope for HIE to support NNZ-2591 Company Update
▸ 8 Sep 2025, 19:08 Change of Director's Interest Notice Director Interests
▸ 28 Aug 2025, 16:43 Application for quotation of securities - NEU Securities Administration
▸ 27 Aug 2025, 11:21 Investor Presentation, 27 August 2025 Presentations
▸ 27 Aug 2025, 09:24 H1 2025 profit after tax A$15m, up from A$8m in H1 2024 Financial Results
▸ 27 Aug 2025, 09:21 Half Yearly Report and Accounts Financial Results
▸ 25 Aug 2025, 09:27 First site initiated for Neuren's PMS Phase 3 trial Company Update
▸ 12 Aug 2025, 16:12 Application for quotation of securities - NEU Securities Administration